XA 001
Alternative Names: XA-001Latest Information Update: 18 Jan 2024
At a glance
- Originator Allero Therapeutics
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 18 Jan 2024 Allero Therapeutics has patents pending for XA 001 (Allero Therapeutics pipeline January 2024)
- 04 Jan 2024 XA 001 is available for licensing as of 04 Jan 2024 (Allero Therapeutics pipeline, January 2024)
- 03 Jan 2024 Early research in Autoimmune disorders in Netherlands (transmucosal) (Allero Therapeutics pipeline, January 2024)